178 related articles for article (PubMed ID: 20214962)
1. Development of pegylated liposomal vinorelbine formulation using "post-insertion" technology.
Li CL; Cui JX; Wang CX; Zhang L; Li YH; Zhang L; Xiu X; Li YF; Wei N
Int J Pharm; 2010 May; 391(1-2):230-6. PubMed ID: 20214962
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
[TBL] [Abstract][Full Text] [Related]
3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
Webb MS; Johnstone S; Morris TJ; Kennedy A; Gallagher R; Harasym N; Harasym T; Shew CR; Tardi P; Dragowska WH; Mayer LD; Bally MB
Eur J Pharm Biopharm; 2007 Mar; 65(3):289-99. PubMed ID: 17123800
[TBL] [Abstract][Full Text] [Related]
5. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
6. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
8. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
[TBL] [Abstract][Full Text] [Related]
9. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate.
Zhang H; Wang ZY; Gong W; Li ZP; Mei XG; Lv WL
Int J Pharm; 2011 Jul; 414(1-2):56-62. PubMed ID: 21596128
[TBL] [Abstract][Full Text] [Related]
10. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro.
Wan F; You J; Sun Y; Zhang XG; Cui FD; Du YZ; Yuan H; Hu FQ
Int J Pharm; 2008 Jul; 359(1-2):104-10. PubMed ID: 18450394
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
[TBL] [Abstract][Full Text] [Related]
12. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
13. Sulfosalicylate mediates improved vinorelbine loading into LUVs and antineoplastic effects.
Li C; Cui J; Wang C; Cao J; Zhang L; Li Y; Liang M; Xiu X; Li Y; Wei N; Deng C
J Liposome Res; 2012 Mar; 22(1):42-54. PubMed ID: 21696260
[TBL] [Abstract][Full Text] [Related]
14. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
15. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
17. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
[TBL] [Abstract][Full Text] [Related]
18. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
Li C; Cui J; Wang C; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
Int J Pharm; 2008 Oct; 362(1-2):60-6. PubMed ID: 18598745
[TBL] [Abstract][Full Text] [Related]
19. A near-infrared two-photon-sensitive peptide-mediated liposomal delivery system.
Yang Y; Yang Y; Xie X; Cai X; Wang Z; Gong W; Zhang H; Li Y; Mei X
Colloids Surf B Biointerfaces; 2015 Apr; 128():427-438. PubMed ID: 25766920
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
